Peptide Coverage Analysis of Recombinant Protein Drugs

Recombinant protein drugs refer to protein products that originate from animals and plants and are developed through biotechnology research. These proteins have certain biological activities and can prevent, treat, and diagnose diseases in humans, animals, and plants. Compared to small molecule drugs, recombinant protein drugs have the advantages of high activity, high specificity, and low toxicity, attracting extensive attention from researchers. Currently, recombinant protein drugs have been widely used in multiple fields such as tumors, autoimmune diseases, metabolic diseases, geriatric diseases, and degenerative diseases. Peptide coverage refers to the degree of match between the protein/polypeptide amino acid sequence detected in actual experiments and the theoretical sequence. In the analysis of recombinant protein drugs, peptide coverage has great significance in determining the credibility of protein primary structure identification. The higher the peptide coverage, the higher the credibility of the identified recombinant protein drug.

 

During the identification process of recombinant protein drugs, Trypsin is usually used to proteolytically cleave the protein, and the identified peptide coverage rate is about 60%. To obtain the complete sequence information of recombinant protein drugs, MtoZ Biolabs Biotechnology has chosen six commonly used protein enzymes (Trypsin, Chymotrypsin, Asp-N, Glu-C, Lys-C, and Lys-N) for proteolytic cleavage and identification of target proteins. By obtaining more fragmented peptide fragments and completing the protein sequence 100% through peptide splicing.

 

MtoZ Biolabs provides customers with drug quality research services that comply with global pharmaceutical regulations. We apply our existing mass spectrometry technology platform to provide you with peptide coverage analysis based on LC-MS/MS. This analysis can be used to confirm whether the recombinant protein drug is fully expressed, to detect whether there is a break in the expression process of the recombinant protein drug, mainly used for protein primary structure confirmation. Through the sequencing of peptides using multiple protease digestion reactions and liquid chromatography-mass spectrometry techniques, combined with proprietary analysis software, the mass spectrometry data of any non-specific proteinase digestion products are analyzed to achieve 100% coverage of the sequenced recombinant protein drug sequence.